Paul de Klaver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paul de Klaver has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Annick de Vries
Sanquin Research
2 shared publicationsFrank Hoentjen
University of Alberta
2 shared publicationsInge Kuntzel
Maxima Medical Centre
2 shared publicationsLisa Smits
Universitair Medisch Centrum Sint Radboud
2 shared publicationsLuc Derijks
Maxima Medical Center
2 shared publicationsLuc J. J. Derijks
Department of Clinical Pharmacy and Pharmacology, Máxima Medical Center, Veldhoven, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 15
Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab
Background/Objectives: Two clinical decision support tools (CDSTs) have been developed to predict treatment effectiveness of vedolizumab in Crohn’s disease (CD) and ulcerative colitis (UC). This study aimed to validate the CDSTs with real-world data from a Dutch teaching hospital. Methods: Patients with CD or UC treated with vedolizumab between October 2014 and July 2023 were included. IBD patients treated with ustekinumab were included to study the specificity of the CDSTs. The primary outcomes were rates of clinical remission (CREM), biochemical remission (BioREM), composite (either clinical or biochemical) remission (CompREM) and corticosteroid-free clinical remission (CSF-CREM) at week 14, 30 and 54. Results: 32 CD patients and 41 UC patients treated with vedolizumab were included, as well as 28 CD patients treated with ustekinumab and 41 UC patients treated with vedolizumab. Among UC patients treated with vedolizumab, rates of CREM, CompREM and CSF-CREM at week 54 were statistically significantly higher in the group with high probability of response compared to the group with low + intermediate probability of response (CREM 33.3% vs. 81.8% p = 0.003; CompREM 33.3% vs. 86.4% p < 0.001; CSF-CREM 22.2% vs. 77.3% p = 0.001). For both CD patients treated with vedolizumab and CD patients treated with ustekinumab, no statistically significant differences were found between low + intermediate and high probability groups for all outcomes. Conclusions: The CDST for UC is able to predict various effectiveness outcomes for treatment with vedolizumab and can therefore help in the selection of optimal treatment for patients with UC. For CD patients treated with vedolizumab, the CDST could not predict effectiveness outcomes.
- 22 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 15
Open AccessRetrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab
Background/Objectives: Two clinical decision support tools (CDSTs) have been developed to predict treatment effectiveness of vedolizumab in Crohn’s disease (CD) and ulcerative colitis (UC). This study aimed to validate the CDSTs with real-world data from a Dutch teaching hospital. Methods: Patients with CD or UC treated with vedolizumab between October 2014 and July 2023 were included. IBD patients treated with ustekinumab were included to study the specificity of the CDSTs. The primary outcomes were rates of clinical remission (CREM), biochemical remission (BioREM), composite (either clinical or biochemical) remission (CompREM) and corticosteroid-free clinical remission (CSF-CREM) at week 14, 30 and 54. Results: 32 CD patients and 41 UC patients treated with vedolizumab were included, as well as 28 CD patients treated with ustekinumab and 41 UC patients treated with vedolizumab. Among UC patients treated with vedolizumab, rates of CREM, CompREM and CSF-CREM at week 54 were statistically significantly higher in the group with high probability of response compared to the group with low + intermediate probability of response (CREM 33.3% vs. 81.8% p = 0.003; CompREM 33.3% vs. 86.4% p < 0.001; CSF-CREM 22.2% vs. 77.3% p = 0.001). For both CD patients treated with vedolizumab and CD patients treated with ustekinumab, no statistically significant differences were found between low + intermediate and high probability groups for all outcomes. Conclusions: The CDST for UC is able to predict various effectiveness outcomes for treatment with vedolizumab and can therefore help in the selection of optimal treatment for patients with UC. For CD patients treated with vedolizumab, the CDST could not predict effectiveness outcomes.
- Open Access
A Scenario-based Model Predictive Control Scheme for Pandemic Response through Non-pharmaceutical Interventions
This paper presents a scenario-based model predictive control (MPC) scheme designed to control an evolving pandemic via non-pharmaceutical intervention (NPIs). The proposed approach combines predictions of possible pandemic evolution to decide on a level of severity of NPIs to be implemented over multiple weeks to maintain hospital pressure below a prescribed threshold, while minimizing their impact on society. Specifically, we first introduce a compartmental model which divides the population into Susceptible, Infected, Detected, Threatened, Healed, and Expired (SIDTHE) subpopulations and describe its positive invariant set. This model is expressive enough to explicitly capture the fraction of hospitalized individuals while preserving parameter identifiability w.r.t. publicly available datasets. Second, we devise a scenario-based MPC scheme with recourse actions that captures potential uncertainty of the model parameters. e.g., due to population behavior or seasonality. Our results show that the scenario-based nature of the proposed controller manages to adequately respond to all scenarios, keeping the hospital pressure at bay also in very challenging situations when conventional MPC methods fail.
Open AccessA Scenario-based Model Predictive Control Scheme for Pandemic Response through Non-pharmaceutical Interventions
This paper presents a scenario-based model predictive control (MPC) scheme designed to control an evolving pandemic via non-pharmaceutical intervention (NPIs). The proposed approach combines predictions of possible pandemic evolution to decide on a level of severity of NPIs to be implemented over multiple weeks to maintain hospital pressure below a prescribed threshold, while minimizing their impact on society. Specifically, we first introduce a compartmental model which divides the population into Susceptible, Infected, Detected, Threatened, Healed, and Expired (SIDTHE) subpopulations and describe its positive invariant set. This model is expressive enough to explicitly capture the fraction of hospitalized individuals while preserving parameter identifiability w.r.t. publicly available datasets. Second, we devise a scenario-based MPC scheme with recourse actions that captures potential uncertainty of the model parameters. e.g., due to population behavior or seasonality. Our results show that the scenario-based nature of the proposed controller manages to adequately respond to all scenarios, keeping the hospital pressure at bay also in very challenging situations when conventional MPC methods fail.
- Open Access
- 31 January 2024
- Published by Wiley
Early model-based precision-dosing at home to guide adalimumab therapy
1. Aims Underdosing of adalimumab can result in non-response and poor disease control. In this study we investigated the prediction of adalimumab levels with population pharmacokinetic model-based Bayesian forecasting early in therapy. This way underexposed non-responders can possibly be identified early to optimise disease control. 2. Methods A literature study was performed to identify adalimumab pharmacokinetic models. With data from a previous pharmacokinetic adalimumab study a model was evaluated retrospectively. In the prospective phase, a fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease patients with peak, trough and control adalimumab samples obtained by a volumetric absorptive microsampling technique and administration data from an electronic needle container. Steady state adalimumab levels were predicted from peak and trough levels collected after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalized root mean square error (RMSE). 3. Results An existing pharmacokinetic model was selected with external validation for the prospective phase. Thirty-six patients (22 rheumatologic and 14 IBD) were included in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was -2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum levels falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable levels of anti-adalimumab antibodies. 4. Conclusion This prospective study demonstrates that adalimumab levels at steady state can be predicted from early samples. This concept enables early precision dosing at home to guide therapy.
- 31 January 2024
- Published by Wiley
Open AccessEarly model-based precision-dosing at home to guide adalimumab therapy
1. Aims Underdosing of adalimumab can result in non-response and poor disease control. In this study we investigated the prediction of adalimumab levels with population pharmacokinetic model-based Bayesian forecasting early in therapy. This way underexposed non-responders can possibly be identified early to optimise disease control. 2. Methods A literature study was performed to identify adalimumab pharmacokinetic models. With data from a previous pharmacokinetic adalimumab study a model was evaluated retrospectively. In the prospective phase, a fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease patients with peak, trough and control adalimumab samples obtained by a volumetric absorptive microsampling technique and administration data from an electronic needle container. Steady state adalimumab levels were predicted from peak and trough levels collected after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalized root mean square error (RMSE). 3. Results An existing pharmacokinetic model was selected with external validation for the prospective phase. Thirty-six patients (22 rheumatologic and 14 IBD) were included in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was -2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum levels falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable levels of anti-adalimumab antibodies. 4. Conclusion This prospective study demonstrates that adalimumab levels at steady state can be predicted from early samples. This concept enables early precision dosing at home to guide therapy.
- 15 June 2023
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 48 (4) , 377-385
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
Background and Objective Underdosing of adalimumab can result in non-response and poor disease control in patients with rheumatic disease or inflammatory bowel disease. In this pilot study we aimed to predict adalimumab concentrations with population pharmacokinetic model-based Bayesian forecasting early in therapy. Methods Adalimumab pharmacokinetic models were identified with a literature search. A fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease (IBD) patients with adalimumab peak (first dose) and trough samples (first and seventh dose) obtained by a volumetric absorptive microsampling technique. Steady state adalimumab concentrations were predicted after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalised root mean square error (RMSE). Results Thirty-six patients (22 rheumatologic and 14 IBD) were analysed in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was −2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum concentrations falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable concentrations of anti-adalimumab antibodies. Conclusion This prospective study demonstrates that adalimumab concentrations at steady state can be predicted from early samples during the induction phase. Clinical Trial Registration The trial was registered in the Netherlands Trial Register with trial registry number NTR 7692 (www.trialregister.nl).
- 15 June 2023
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 48 (4) , 377-385
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
Background and Objective Underdosing of adalimumab can result in non-response and poor disease control in patients with rheumatic disease or inflammatory bowel disease. In this pilot study we aimed to predict adalimumab concentrations with population pharmacokinetic model-based Bayesian forecasting early in therapy. Methods Adalimumab pharmacokinetic models were identified with a literature search. A fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease (IBD) patients with adalimumab peak (first dose) and trough samples (first and seventh dose) obtained by a volumetric absorptive microsampling technique. Steady state adalimumab concentrations were predicted after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalised root mean square error (RMSE). Results Thirty-six patients (22 rheumatologic and 14 IBD) were analysed in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was −2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum concentrations falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable concentrations of anti-adalimumab antibodies. Conclusion This prospective study demonstrates that adalimumab concentrations at steady state can be predicted from early samples during the induction phase. Clinical Trial Registration The trial was registered in the Netherlands Trial Register with trial registry number NTR 7692 (www.trialregister.nl).
- 27 July 2022
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 42 (9) , 787-789
Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report
- 27 July 2022
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 42 (9) , 787-789
Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report
- Open Access
Optimizing Vaccine Allocation Strategies in Pandemic Outbreaks: An Optimal Control Approach
Since early 2020, the world has been dealing with a raging pandemic outbreak: COVID-19. A year later, vaccines have become accessible, but in limited quantities, so that governments needed to devise a strategy to decide which part of the population to prioritize when assigning the available doses, and how to manage the interval between doses for multi-dose vaccines. In this paper, we present an optimization framework to address the dynamic double-dose vaccine allocation problem whereby the available vaccine doses must be administered to different age-groups to minimize specific societal objectives. In particular, we first identify an age-dependent Susceptible-Exposed-Infected-Recovered (SEIR) epidemic model including an extension capturing partially and fully vaccinated people, whereby we account for age-dependent immunity and infectiousness levels together with disease severity. Second, we leverage our model to frame the dynamic age-dependent vaccine allocation problem for different societal objectives, such as the minimization of infections or fatalities, and solve it with nonlinear programming techniques. Finally, we carry out a numerical case study with real-world data from The Netherlands. Our results show how different societal objectives can significantly alter the optimal vaccine allocation strategy. For instance, we find that minimizing the overall number of infections results in delaying second doses, whilst to minimize fatalities it is important to fully vaccinate the elderly first.
Open AccessOptimizing Vaccine Allocation Strategies in Pandemic Outbreaks: An Optimal Control Approach
Since early 2020, the world has been dealing with a raging pandemic outbreak: COVID-19. A year later, vaccines have become accessible, but in limited quantities, so that governments needed to devise a strategy to decide which part of the population to prioritize when assigning the available doses, and how to manage the interval between doses for multi-dose vaccines. In this paper, we present an optimization framework to address the dynamic double-dose vaccine allocation problem whereby the available vaccine doses must be administered to different age-groups to minimize specific societal objectives. In particular, we first identify an age-dependent Susceptible-Exposed-Infected-Recovered (SEIR) epidemic model including an extension capturing partially and fully vaccinated people, whereby we account for age-dependent immunity and infectiousness levels together with disease severity. Second, we leverage our model to frame the dynamic age-dependent vaccine allocation problem for different societal objectives, such as the minimization of infections or fatalities, and solve it with nonlinear programming techniques. Finally, we carry out a numerical case study with real-world data from The Netherlands. Our results show how different societal objectives can significantly alter the optimal vaccine allocation strategy. For instance, we find that minimizing the overall number of infections results in delaying second doses, whilst to minimize fatalities it is important to fully vaccinate the elderly first.
- Open Access
- 16 August 2021
- Published by Wiley
Leflunomide during pregnancy; a case report and review of the literature
Leflunomide is a prodrug for teruflunomide and used for rheumatic diseases. Teriflunomide is considered to be teratogenic and should be avoided in pregnancy. We describe a case of teriflunomide exposure up to the third trimester of pregnancy. A healthy baby was delivered, despite substantial drug exposure. Multiple washout procedures were required to reduce teriflunomide concentrations below the safe target concentration 0.02 mg/L.
- 16 August 2021
- Published by Wiley
Open AccessLeflunomide during pregnancy; a case report and review of the literature
Leflunomide is a prodrug for teruflunomide and used for rheumatic diseases. Teriflunomide is considered to be teratogenic and should be avoided in pregnancy. We describe a case of teriflunomide exposure up to the third trimester of pregnancy. A healthy baby was delivered, despite substantial drug exposure. Multiple washout procedures were required to reduce teriflunomide concentrations below the safe target concentration 0.02 mg/L.
- Open Access
- 9 December 2009
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 80 (6) , 734-736
High systemic gentamicin levels and ototoxicity after implantation of gentamicin beads in a 70-year-old man—a case report
Gentamicin beads are used for musculoskeletal infections. Gentamicin is released gradually from the beads, and high gentamicin concentrations are achieved only locally. Side effects of gentamicin a...
- 9 December 2009
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 80 (6) , 734-736
Open AccessHigh systemic gentamicin levels and ototoxicity after implantation of gentamicin beads in a 70-year-old man—a case report
Gentamicin beads are used for musculoskeletal infections. Gentamicin is released gradually from the beads, and high gentamicin concentrations are achieved only locally. Side effects of gentamicin a...